Bellevue Group Portfolio holdings
Bellevue Group is a Swiss asset manager that focuses on healthcare investing, small and mid-cap companies and other growth strategies. Martin Bisang and four other founders started it in 1993, and through its subsidiary Bank am Bellevue it first became a major name in brokerage and block trading on the Swiss market. It sold that bank to Luxembourg's KBL Group in 2019, dropping its private client business and becoming a pure asset manager. In 2016 it bought the German asset manager StarCapital to build its presence in Germany, and in 2023 it launched Bellevue Obesity Solutions, a global equity fund.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Illumina
ILMN
|
+$10.5M |
| 2 |
Align Technology
ALGN
|
+$9.7M |
| 3 |
CELG
Celgene
CELG
|
+$9.6M |
| 4 |
Elevance Health
ELV
|
+$9.1M |
| 5 |
Cencora
COR
|
+$7.21M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$7.35M |
| 2 |
Cigna
CI
|
+$4.96M |
| 3 |
BCR
CR Bard
BCR
|
+$4.65M |
| 4 |
Centene
CNC
|
+$4.38M |
| 5 |
Alkermes
ALKS
|
+$4.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.4% |
| 2 | Financials | 0.94% |
| 3 | Industrials | 0.35% |
| 4 | Miscellaneous | 0.31% |
Similar funds
Bellevue Group's Q3 2017 Portfolio in Review
As of Q3 2017, Bellevue Group held 136 positions worth $956M, up 13% from $846M the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Bellevue Group deployed $88M of net new capital in Q3 2017, opening 4 new positions and adding to 63 existing holdings. Its largest new stake was Henry Schein: 48,450 shares worth $3.12M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Medtronic, an estimated $7.35M trimmed.
- Bellevue Group's largest Q3 2017 buy was Henry Schein: 48,450 shares worth $3.12M.
- Bellevue Group added most to Illumina in Q3 2017, an estimated $10.5M increase.
- Bellevue Group's biggest Q3 2017 reduction was Medtronic, cutting an estimated $7.35M.
- Bellevue Group fully exited China Biologic Products Holdings in Q3 2017, selling an estimated $4.1M.
- Bellevue Group's ten largest holdings make up 34% of its $956M portfolio in Q3 2017.
- Bellevue Group opened 4 new positions and closed 5 in Q3 2017.
- Bellevue Group's portfolio value rose 13% quarter-over-quarter to $956M.
Based on Bellevue Group's 13F filing for Q3 2017, filed 13 Nov 2017.